Instrumento Inactivo

Otros idiomas Cardium Therapeutics Inc Nyse

Acciones

US1419161062

Precio de cierre Nyse Otros sitios de cotización
- ^USD	-

2022	Gene Biotherapeutics, Inc. El auditor plantea la duda de la "empresa en funcionamiento	CI
2021	Gene Biotherapeutics, Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2020	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

GENE BIOTHERAPEUTICS, INC. - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	14/04/22
GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	30/03/22
Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	30/03/22
GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	27/10/21
GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	03/09/21
Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	03/09/21
GENE BIOTHERAPEUTICS : Changes in Registrant's Certifying Accountant (form 8-K/A)	09/08/21
GENE BIOTHERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant (form 8-K)	05/08/21
GENE BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	28/07/21
Gene Biotherapeutics, Inc. Announces Resignation of Murray H. Hutchison from the Board	28/07/21
GENE BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	26/04/21
Gene Biotherapeutics Inc. Enters into an Agreement with Fujifilm Diosynth Biotechnologies to Manufacture the Generx Angiogenic Gene Therapy Product	26/04/21
GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23/04/21
GENE BIOTHERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	28/05/20
Gene Biotherapeutics, Inc. Announces Management Changes	28/05/20
Gene Biotherapeutics, Inc. Appoints James L. Grainer as Chief Financial Officer	28/05/20
Gene Biotherapeutics, Inc. announced that it has received $1.7 million in funding from Nostrum Pharmaceuticals LLC	22/05/20
Gene Biotherapeutics Inc. Announces Retirement of Gerald J. Lewis from its Board of Directors	20/03/19
Gene Biotherapeutics Inc. Enters into an Agreement with the Olaregen Therapeutix Inc	13/09/18
Gene Biotherapeutics Mulls Acquisitions	08/01/18

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Cardium Therapeutics Inc Nyse

Acciones

US1419161062

Otros idiomas

Filtros